Given the success of checkpoint inhibitors and the desire to test them in combination with other immunotherapies and targeted therapies, hundreds of clinical trials have been launched. To most efficiently study these agents, researchers and the FDA are exploring the use of novel endpoints, the use of new preclinical models, and adaptive trial designs. However, the cost and demands associated with the conduct of increasingly sophisticated early-phase clinical trials are putting smaller companies and some academic medical centers at a disadvantage.
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2z75iAO
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου